[Correspondence] Alternative approaches to risk–benefit balancing in immunotherapy

April, 04, 2024 | Select Oncology Journal Articles

We read with great interest the Editorial in The Lancet Oncology1 sharing the Editors’ perspectives on the risk–benefit balance of immunotherapies. Although we agree with their viewpoints, we advocate caution in recommending options like prophylactic tocilizumab due to inadequate robust supporting data. Furthermore, we wish to highlight alternative approaches for effective risk optimisation and cost-effectiveness.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy